{"id":10970,"date":"2025-08-20T06:37:07","date_gmt":"2025-08-20T06:37:07","guid":{"rendered":"https:\/\/www.europesays.com\/ie\/10970\/"},"modified":"2025-08-20T06:37:07","modified_gmt":"2025-08-20T06:37:07","slug":"an-updated-systematic-review-and-meta-analysis-correlation-between-circulating-plasminogen-activator-inhibitor-1-levels-and-metabolic-dysfunction-associated-steatotic-liver-disease-bmc-gastroentero","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ie\/10970\/","title":{"rendered":"An updated systematic review and meta-analysis: correlation between circulating plasminogen activator inhibitor-1 levels and metabolic dysfunction-associated steatotic liver disease | BMC Gastroenterology"},"content":{"rendered":"
  • \n

    Pet\u00e4j\u00e4 EM, Yki-J\u00e4rvinen H. Definitions of normal liver fat and the association of insulin sensitivity with acquired and genetic NAFLD-A systematic review. Int J Mol Sci. 2016. https:\/\/doi.org\/10.3390\/ijms17050633<\/a>.<\/p>\n

    Article<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n     PubMed Central<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Cobbina E, Akhlaghi F. Non-alcoholic fatty liver disease (NAFLD) – pathogenesis, classification, and effect on drug metabolizing enzymes and transporters. Drug Metab Rev. 2017;49(2):197\u2013211. https:\/\/doi.org\/10.1080\/03602532.2017.1293683<\/a>.<\/p>\n

    Article<\/a>\u00a0
    \n     CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n     PubMed Central<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Rinella ME, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Ann Hepatol. 2024;29(1): 101133. https:\/\/doi.org\/10.1016\/j.aohep.2023.101133<\/a>.<\/p>\n

    Article<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Eslam M, George J. MASLD: now is the time to capitalize on the momentum. J Hepatol. 2021;74(5):1262\u20133. https:\/\/doi.org\/10.1016\/j.jhep.2021.02.002<\/a>.<\/p>\n

    Article<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    \n Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73(1):202\u20139. https:\/\/doi.org\/10.1016\/j.jhep.2020.03.039<\/a>.<\/p>\n

    Article<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Adams LA, Angulo P. Recent concepts in non-alcoholic fatty liver disease. Diabet Med. Sep 2005;22(9):1129\u201333. https:\/\/doi.org\/10.1111\/j.1464-5491.2005.01748.x<\/a>.<\/p>\n<\/li>\n

  • \n

    Eslam M, Sanyal AJ, George J. MASLD: A Consensus-Driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology May. 2020;158(7):1999\u2013e20141. https:\/\/doi.org\/10.1053\/j.gastro.2019.11.312<\/a>.<\/p>\n

    Article<\/a>\u00a0
    \n     CAS<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Younossi Z, Tacke F, Arrese M, et al. Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology. 2019;69(6):2672\u201382. https:\/\/doi.org\/10.1002\/hep.30251<\/a>.<\/p>\n

    Article<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Masoodi M, Gastaldelli A, Hy\u00f6tyl\u00e4inen T, et al. Metabolomics and lipidomics in NAFLD: biomarkers and non-invasive diagnostic tests. Nat Rev Gastroenterol Hepatol. 2021;18(12):835\u201356. https:\/\/doi.org\/10.1038\/s41575-021-00502-9<\/a>.<\/p>\n

    Article<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Angulo P, Kleiner DE, Dam-Larsen S, et al. Liver fibrosis, but no other histologic features, is associated with Long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology Aug. 2015;149(2):389\u2013e9710. https:\/\/doi.org\/10.1053\/j.gastro.2015.04.043<\/a>.<\/p>\n

    Article<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Kruithof EK. Plasminogen activator inhibitors\u2013a review. Enzyme. 1988;40(2\u20133):113\u201321. https:\/\/doi.org\/10.1159\/000469153<\/a>.<\/p>\n

    Article<\/a>\u00a0
    \n     CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Levine JA, Oleaga C, Eren M, et al. Role of PAI-1 in hepatic steatosis and dyslipidemia. Sci Rep. 2021;11(1): 430. https:\/\/doi.org\/10.1038\/s41598-020-79948-x<\/a>.<\/p>\n

    Article<\/a>\u00a0
    \n     CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n     PubMed Central<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Alessi MC, Juhan-Vague I. PAI-1 and the metabolic syndrome: links, causes, and consequences. Arterioscler Thromb Vasc Biol. 2006;26(10):2200\u20137. https:\/\/doi.org\/10.1161\/01.Atv.0000242905.41404.68<\/a>.<\/p>\n

    Article<\/a>\u00a0
    \n     CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Kaji H. Adipose Tissue-Derived plasminogen activator Inhibitor-1 function and regulation. Compr Physiol Sep. 2016;15(4):1873\u201396. https:\/\/doi.org\/10.1002\/cphy.c160004<\/a>.<\/p>\n

    Article<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Jin R, Krasinskas A, Le NA, Konomi JV, Holzberg J, Romero R, et al. Association between plasminogen activator inhibitor-1 and severity of liver injury and cardiovascular risk in children with non-alcoholic fatty liver disease. Pediatr Obes. 2018;13(1):23\u20139. https:\/\/doi.org\/10.1111\/ijpo.12183<\/a>.<\/p>\n

    Article<\/a>\u00a0
    \n     CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Higgins JPT, Thomas J, Chandler J, (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.5. Cochrane. 2024. www.training.cochrane.org\/handbook<\/a>. Accessed 24 August 2024.<\/p>\n<\/li>\n

  • \n

    Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Syst Rev. 2021;10(1):89. https:\/\/doi.org\/10.1186\/s13643-021-01626-4<\/a>.<\/p>\n

    Article<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n     PubMed Central<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Lin S, Huang J, Wang M, Kumar R, Liu Y, Liu S, et al. Comparison of MASLD and NAFLD diagnostic criteria in real world. Liver Int. 2020;40(9):2082\u20139. https:\/\/doi.org\/10.1111\/liv.14548<\/a>.<\/p>\n

    Article<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Stang A. Critical evaluation of the Newcastle-ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603\u20135. https:\/\/doi.org\/10.1007\/s10654-010-9491-z<\/a>.<\/p>\n

    Article<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range. BMC Med Res Methodol. 2014;14:135. https:\/\/doi.org\/10.1186\/1471-2288-14-135<\/a>.<\/p>\n

    Article<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n     PubMed Central<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Luo D, Wan X, Liu J, Tong T. Optimally estimating the sample mean from the sample size, median, mid-range, and\/or mid-quartile range. Stat Methods Med Res. 2018;27(6):1785\u2013805. https:\/\/doi.org\/10.1177\/0962280216669183<\/a>.<\/p>\n

    Article<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Schmidt FL, Oh IS, Hayes TL. Fixed- versus random-effects models in meta-analysis: model properties and an empirical comparison of differences in results. Br J Math Stat Psychol. 2009;62(Pt 1):97\u2013128. https:\/\/doi.org\/10.1348\/000711007×255327<\/a>.<\/p>\n

    Article<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557\u201360. https:\/\/doi.org\/10.1136\/bmj.327.7414.557<\/a>.<\/p>\n

    Article<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n     PubMed Central<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    \n Younossi ZM. Non-alcoholic fatty liver disease – a global public health perspective. J Hepatol. 2019;70(3):531\u201344. https:\/\/doi.org\/10.1016\/j.jhep.2018.10.033<\/a>.<\/p>\n

    Article<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Abdel-Razik A, Mousa N, Shabana W, Yassen AH, Abdelsalam M, Wahba MM, et al. De Novo portal vein thrombosis in Non-Cirrhotic Non-Alcoholic fatty liver disease: A 9-Year prospective cohort study. Front Med (Lausanne). 2021;8:650818. https:\/\/doi.org\/10.3389\/fmed.2021.650818<\/a>.<\/p>\n

    Article<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Alvares-da-Silva MR, de Oliveira CP, Stefano JT, Barbeiro HV, Barbeiro D, Soriano FG, et al. Pro-atherosclerotic markers and cardiovascular risk factors one year after liver transplantation. World J Gastroenterol. 2014;20(26):8667\u201373. https:\/\/doi.org\/10.3748\/wjg.v20.i26.8667<\/a>.<\/p>\n

    Article<\/a>\u00a0
    \n     CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n     PubMed Central<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Bai XP, Yang YL, Gao M, Li X, Zhao BZ. The influence of serum triglycerides on plasminogen activator inhibitor-1 and adiponectin in patients with nonalcoholic fatty liver disease. Chin J Gastroenterol Hepatol. 2014;23(04):435\u20137.<\/p>\n

    CAS<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Bilgir O, Bilgir F, Bozkaya G, Calan M. Changes in the levels of endothelium-derived coagulation parameters in nonalcoholic fatty liver disease. Blood Coagul Fibrinolysis. 2014;25(2):151\u20135. https:\/\/doi.org\/10.1097\/mbc.0000000000000009<\/a>.<\/p>\n

    Article<\/a>\u00a0
    \n     CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Cao Y, Li L. Relationship of non-alcoholic steatohepatitis with arterial endothelial function and atherosclerosis. Chin J Hepatol. 2014;22(3):205\u20138. https:\/\/doi.org\/10.3760\/cma.j.issn.1007-3418.2014.03.012<\/a>.<\/p>\n

    Article<\/a>\u00a0
    \n     CAS<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Chang ML, Hsu CM, Tseng JH, Tsou YK, Chen SC, Shiau SS, et al. Plasminogen activator inhibitor-1 is independently associated with non-alcoholic fatty liver disease whereas leptin and adiponectin vary between genders. J Gastroenterol Hepatol. 2015;30(2):329\u201336. https:\/\/doi.org\/10.1111\/jgh.12705<\/a>.<\/p>\n

    Article<\/a>\u00a0
    \n     CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Chen HY, Zhu SW, Wu WJ, Bu RF. Effect of serum triglyceride on PAI-1 and APN levels in patients with nonalcoholic fatty liver disease. Mod Diagn Treat. 2015;26(15):3375\u20137.<\/p>\n


    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Deng YQ, Fan XF, Li JP. Fibrinolytic status in nonalcoholic fatty liver patients with different glucose tolerance levels. Zhejiang J Integr Traditional Chin Western Med. 2005(09):547\u20138.<\/p>\n<\/li>\n

  • \n

    Deng YQ, Fan XF, Li YD. Relationship between phlegm-stasis syndrome and fibrinolytic status in patients with non-alcoholic fatty liver. Chin J Integr Tradit Western Med. 2005;25(1):22\u20134.<\/p>\n

    CAS<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Fang LM, Shen NY, Ma QH, Chen KL, Liu D. Changes and significance of plasminogen activator inhibitor-1 level in nonalcoholic fatty liver disease. Chin J Practical Med. 2010;37(13):74\u20135. https:\/\/doi.org\/10.3760\/cma.j.issn.1674-4756.2010.13.036<\/a>.<\/p>\n

    Article<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Jiang X, Sun M. Changes and clinical significance of serum PAI-1 in nonalcoholic fatty liver disease. Chin J Lab Diagn. 2020;24(06):953\u20135.<\/p>\n


    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Kargili A, Cipil H, Karakurt F, Kasapoglu B, Koca C, Aydin M, et al. Hemostatic alterations in fatty liver disease. Blood Coagul Fibrinolysis. 2010;21(4):325\u20137. https:\/\/doi.org\/10.1097\/mbc.0b013e328337b3f8<\/a>.<\/p>\n

    Article<\/a>\u00a0
    \n     CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    \n Li Y, Liu L, Wang B, Wang J, Chen D. Simple steatosis is a more relevant source of serum inflammatory markers than omental adipose tissue. Clin Res Hepatol Gastroenterol. 2014;38(1):46\u201354. https:\/\/doi.org\/10.1016\/j.clinre.2013.08.006<\/a>.<\/p>\n

    Article<\/a>\u00a0
    \n     CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Nier A, Huber Y, Labenz C, Michel M, Bergheim I, Schattenberg JM. Adipokines and endotoxemia correlate with hepatic steatosis in non-alcoholic fatty liver disease (NAFLD). Nutrients. 2020. https:\/\/doi.org\/10.3390\/nu12030699<\/a>.<\/p>\n

    Article<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n     PubMed Central<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Targher G, Bertolini L, Rodella S, Lippi G, Franchini M, Zoppini G, et al. NASH predicts plasma inflammatory biomarkers independently of visceral fat in men. Obesity. 2008;16(6):1394\u20139. https:\/\/doi.org\/10.1038\/oby.2008.64<\/a>.<\/p>\n

    Article<\/a>\u00a0
    \n     CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    \n Thuy S, Ladurner R, Volynets V, Wagner S, Strahl S, K\u00f6nigsrainer A, et al. Nonalcoholic fatty liver disease in humans is associated with increased plasma endotoxin and plasminogen activator inhibitor 1 concentrations and with fructose intake. J Nutr. 2008;138(8):1452\u20135. https:\/\/doi.org\/10.1093\/jn\/138.8.1452<\/a>.<\/p>\n

    Article<\/a>\u00a0
    \n     CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Tian S, Liu HL, Zhong XQ. Diagnostic significance of serum plasminogen activator inhibitor-1 level for nonalcoholic fatty liver disease. Mod J Integr Traditional Chin Western Med. 2020;29(06):585\u20138.<\/p>\n


    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Volynets V, K\u00fcper MA, Strahl S, Maier IB, Spruss A, Wagnerberger S, et al. Nutrition, intestinal permeability, and blood ethanol levels are altered in patients with nonalcoholic fatty liver disease (NAFLD). Dig Dis Sci. 2012;57(7):1932\u201341. https:\/\/doi.org\/10.1007\/s10620-012-2112-9<\/a>.<\/p>\n

    Article<\/a>\u00a0
    \n     CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Yang YQ, Zhang Y, Kou SJ, Dong L. Study on the relationship between fatty liver severity and oxidative stress,saa, CRP and cerebral arteriosclerosis in fatty liver patients. Chin J Integr Med. 2022;32(6):520\u20134. https:\/\/doi.org\/10.3969\/j.issn.1005-0264.2022.06.012<\/a>.<\/p>\n

    Article<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Xu L, Ding XY, Weng YS, Miu M, Yuan JY. Changes in the coagulation fibrinolysis system in nonalcoholic fatty liver disease. Chin J Rural Med Pharm. 2011;18(11):59\u201360. https:\/\/doi.org\/10.19542\/j.cnki.1006-5180.2011.11.044<\/a>.<\/p>\n

    Article<\/a>\u00a0
    \n     CAS<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Wang C, Yan J, Zhang S, Xie Y, Nie Y, Chen Z, et al. Screening new blood indicators for Non-alcoholic fatty liver disease (NAFLD) diagnosis of Chinese based on machine learning. Front Med (Lausanne). 2022;9:771219. PubMed PMID: 35755070; PubMed Central PMCID: PMCPMC9218755.<\/p>\n

    PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Yener S, Akarsu M, Demir T, Akinci B, Sagol O, Bayraktar F, et al. Plasminogen activator inhibitor-1 and thrombin activatable fibrinolysis inhibitor levels in non-alcoholic steatohepatitis. J Endocrinol Invest. 2007;30(10):810\u20139. https:\/\/doi.org\/10.1007\/bf03349221<\/a>.<\/p>\n

    Article<\/a>\u00a0
    \n     CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Zhu JZ, Zhu HT, Dai YN, Li CX, Fang ZY, Zhao DJ, et al. Serum periostin is a potential biomarker for non-alcoholic fatty liver disease: a case-control study. Endocrine. 2016;51(1):91\u2013100. https:\/\/doi.org\/10.1007\/s12020-015-0735-2<\/a>.<\/p>\n

    Article<\/a>\u00a0
    \n     CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Cariou B, Byrne CD, Loomba R, Sanyal AJ. Nonalcoholic fatty liver disease as a metabolic disease in humans: A literature review. Diabetes Obes Metab. 2021;23(5):1069\u201383. https:\/\/doi.org\/10.1007\/s12020-015-0735-2<\/a>.<\/p>\n

    Article<\/a>\u00a0
    \n     CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n     PubMed Central<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Fassio E, Alvarez E, Dom\u00ednguez N, Landeira G, Longo C. Natural history of nonalcoholic steatohepatitis: a longitudinal study of repeat liver biopsies. Hepatology. 2004;40(4):820\u20136. https:\/\/doi.org\/10.1002\/hep.20410<\/a>.<\/p>\n

    Article<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Chakravarthy MV, Neuschwander-Tetri BA. The metabolic basis of nonalcoholic steatohepatitis. Endocrinology, Diabetes & Metabolism. 2020;3(4): e00112. https:\/\/doi.org\/10.1002\/edm2.112<\/a>.<\/p>\n

    Article<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Cusi K, Chang Z, Harrison S, Lomonaco R, Bril F, Orsak B, et al. Limited value of plasma cytokeratin-18 as a biomarker for NASH and fibrosis in patients with non-alcoholic fatty liver disease. J Hepatol. 2014;60(1):167\u201374. https:\/\/doi.org\/10.1016\/j.jhep.2013.07.042<\/a>.<\/p>\n

    Article<\/a>\u00a0
    \n     CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Hu J, Ke Y, Wu F, Liu S, Ji C, Zhu X, et al. Circulating Irisin levels in patients with nonalcoholic fatty liver disease: A systematic review and Meta-Analysis. Gastroenterol Res Pract. 2020;2020:8818191. https:\/\/doi.org\/10.1155\/2020\/8818191<\/a>.<\/p>\n

    Article<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n     PubMed Central<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Polyzos SA, Aronis KN, Kountouras J, Raptis DD, Vasiloglou MF, Mantzoros CS. Circulating leptin in non-alcoholic fatty liver disease: a systematic review and meta-analysis. Diabetologia. 2016;59(1):30\u201343. https:\/\/doi.org\/10.1007\/s00125-015-3769-3<\/a>.<\/p>\n

    Article<\/a>\u00a0
    \n     CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    \n Agren A, J\u00f6rneskog G, Elgue G, Henriksson P, Wallen H, Wiman B. Increased incorporation of antiplasmin into the fibrin network in patients with type 1 diabetes. Diabetes Care. 2014;37(7):2007\u201314. https:\/\/doi.org\/10.2337\/dc13-1776<\/a>.<\/p>\n

    Article<\/a>\u00a0
    \n     CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Du XL, Edelstein D, Rossetti L, Fantus IG, Goldberg H, Ziyadeh F, et al. Hyperglycemia-induced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing Sp1 glycosylation. Proc Natl Acad Sci USA. 2000;97(22):12222\u20136. https:\/\/doi.org\/10.1073\/pnas.97.22.12222<\/a>.<\/p>\n

    Article<\/a>\u00a0
    \n     CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n     PubMed Central<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Chen YQ, Su M, Walia RR, Hao Q, Covington JW, Vaughan DE. Sp1 sites mediate activation of the plasminogen activator inhibitor-1 promoter by glucose in vascular smooth muscle cells. J Biol Chem. 1998;273(14):8225\u201331.<\/p>\n

    CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Beier JI, Arteel GE. Alcoholic liver disease and the potential role of plasminogen activator inhibitor-1 and fibrin metabolism. Exp Biol Med (Maywood). 2012;237(1):1\u20139. https:\/\/doi.org\/10.1074\/jbc.273.14.8225<\/a>.<\/p>\n

    Article<\/a>\u00a0
    \n     CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Beier JI, Luyendyk JP, Guo L, von Montfort C, Staunton DE, Arteel GE. Fibrin accumulation plays a critical role in the sensitization to lipopolysaccharide-induced liver injury caused by ethanol in mice. Hepatology. 2009;49(5):1545\u201353. https:\/\/doi.org\/10.1002\/hep.22847<\/a>.<\/p>\n

    Article<\/a>\u00a0
    \n     CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Alsharoh H, Ismaiel A, Leucuta DC, Popa SL, Dumitrascu DL. Plasminogen activator inhibitor-1 levels in non-alcoholic fatty liver disease: a systematic review and meta-analysis. J Gastrointestin Liver Dis. 2022;31(2):206\u201314. https:\/\/doi.org\/10.15403\/jgld-4091<\/a>.<\/p>\n

    Article<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Simon TG, Trejo MEP, McClelland R, Bradley R, Blaha MJ, Zeb I, et al. Circulating interleukin-6 is a biomarker for coronary atherosclerosis in nonalcoholic fatty liver disease: results from the multi-ethnic study of atherosclerosis. Int J Cardiol. 2018;259:198\u2013204. https:\/\/doi.org\/10.1016\/j.ijcard.2018.01.046<\/a>.<\/p>\n

    Article<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n     PubMed Central<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Ajmera V, Perito ER, Bass NM, Terrault NA, Yates KP, Gill R, et al. Novel plasma biomarkers associated with liver disease severity in adults with nonalcoholic fatty liver disease. Hepatology. 2017;65(1):65\u201377. https:\/\/doi.org\/10.1002\/hep.28776<\/a>.<\/p>\n

    Article<\/a>\u00a0
    \n     CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Sookoian S, Casta\u00f1o GO, Burgue\u00f1o AL, Rosselli MS, Gianotti TF, Mallardi P, et al. Circulating levels and hepatic expression of molecular mediators of atherosclerosis in nonalcoholic fatty liver disease. Atherosclerosis. 2010;209(2):585\u201391. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2009.10.011<\/a>.<\/p>\n

    Article<\/a>\u00a0
    \n     CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Campbell PT, VanWagner LB, Colangelo LA, Lewis CE, Henkel A, Ajmera VH, et al. Association between plasminogen activator inhibitor-1 in young adulthood and nonalcoholic fatty liver disease in midlife: CARDIA. Liver Int. 2020;40(5):1111\u201320. https:\/\/doi.org\/10.1111\/liv.14417<\/a>.<\/p>\n

    Article<\/a>\u00a0
    \n     CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n     PubMed Central<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Pan JJ, Fallon MB. Gender and Racial differences in nonalcoholic fatty liver disease. World J Hepatol. 2014;6(5):274\u201383. https:\/\/doi.org\/10.4254\/wjh.v6.i5.274<\/a>.<\/p>\n

    Article<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n     PubMed Central<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Romeo S, Kozlitina J, Xing C, Pertsemlidis A, Cox D, Pennacchio LA, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet. 2008;40(12):1461\u20135. https:\/\/doi.org\/10.1038\/ng.257<\/a>.<\/p>\n

    Article<\/a>\u00a0
    \n     CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n     PubMed Central<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Zoratti R. A review on ethnic differences in plasma triglycerides and high-density-lipoprotein cholesterol: is the lipid pattern the key factor for the low coronary heart disease rate in people of African origin? Eur J Epidemiol. 1998;14(1):9\u201321. https:\/\/doi.org\/10.1023\/a:1007492202045<\/a>.<\/p>\n

    Article<\/a>\u00a0
    \n     CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Lomonaco R, Ortiz-Lopez C, Orsak B, Finch J, Webb A, Bril F, et al. Role of ethnicity in overweight and obese patients with nonalcoholic steatohepatitis. Hepatology. 2011;54(3):837\u201345. https:\/\/doi.org\/10.1002\/hep.24483<\/a>.<\/p>\n

    Article<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Souza M, et al. Representation of sex, race and ethnicity in MASH randomised controlled trials: A systematic review and Meta-Analysis. Liver Int. 2025;45(4):e70029. https:\/\/doi.org\/10.1111\/liv.70029<\/a>.<\/p>\n

    Article<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Crudele L, et al. Fatty liver index (FLI) is the best score to predict MASLD with 50% lower cut-off value in women than in men. Biol Sex Differ. 2024;15(1):43. https:\/\/doi.org\/10.1186\/s13293-024-00617-z<\/a>.<\/p>\n

    Article<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n     PubMed Central<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Lonardo A, et al. Sex differences in nonalcoholic fatty liver disease: state of the art and identification of research gaps. Hepatology. 2019;70(4):1457\u201369. https:\/\/doi.org\/10.1002\/hep.30626<\/a>.<\/p>\n

    Article<\/a>\u00a0
    \n     CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Tague BW. Germ-line transformation of Arabidopsis lasiocarpa. Transgenic Res. 2001;10(3):259\u201367. https:\/\/doi.org\/10.1023\/a:1016633617908<\/a>.<\/p>\n

    Article<\/a>\u00a0
    \n     CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Holzberg JR, Jin R, Le NA, Ziegler TR, Brunt EM, McClain CJ, et al. Plasminogen activator Inhibitor-1 predicts quantity of hepatic steatosis independent of insulin resistance and body weight. J Pediatr Gastroenterol Nutr. 2016;62(6):819\u201323. https:\/\/doi.org\/10.1097\/mpg.0000000000001096<\/a>.<\/p>\n

    Article<\/a>\u00a0
    \n     CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n     PubMed Central<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n","protected":false},"excerpt":{"rendered":"Pet\u00e4j\u00e4 EM, Yki-J\u00e4rvinen H. Definitions of normal liver fat and the association of insulin sensitivity with acquired and…\n","protected":false},"author":2,"featured_media":10971,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[78],"tags":[18,1910,135,1912,19,1911,17,656,10609,10610,10611],"class_list":{"0":"post-10970","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-health","8":"tag-eire","9":"tag-gastroenterology","10":"tag-health","11":"tag-hepatology","12":"tag-ie","13":"tag-internal-medicine","14":"tag-ireland","15":"tag-meta-analysis","16":"tag-metabolic-dysfunction-associated-steatotic-liver-disease","17":"tag-non-alcoholic-fatty-liver-disease","18":"tag-plasminogen-activator-inhibitor-1"},"share_on_mastodon":{"url":"","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/10970","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/comments?post=10970"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/10970\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media\/10971"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media?parent=10970"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/categories?post=10970"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/tags?post=10970"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}